---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pathophysiology"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pathophysiology. Topics: Normal function of APOL1: trypanolytic pore-forming protein; Gain-of-function cation channel activity of the G1 and G2 variants; Human genetic evidence: the p.N264K variant blocks pore function; Podocyte injury, proteinuria, and glomerulosclerosis; 2 further topics. 6 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Normal function of APOL1: trypanolytic pore-forming protein

> “The APOL1 gene encodes an innate immune pore-forming protein that inserts into the trypanosome’s lysosomal membrane, inducing osmotic stress and ultimately lysing the trypanosome.”
> “The G1 and G2 variants of the APOL1 gene restored immune protection against the novel T brucei strains and underwent positive selection in West Africa.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “In vitro assays revealed that only the kidney disease-associated ApoL1 variants lysed Trypanosoma brucei rhodesiense.”

Source: [Genovese et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2980843/)

<a id="topic-2.2.1.4-2"></a>

### Gain-of-function cation channel activity of the G1 and G2 variants

> “APOL1 protein can act as an ion channel (pore) in trypanosome and eukaryotic cells.26,49–51 The G1 and G2 variants of APOL1 alter the normal pore-forming function of the APOL1 protein, leading to increased pore activity.”
> “In cell-based models, G0 is generally nontoxic, whereas G1 and G2 express toxic, gain-of-function variants.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Recent experimental evidence suggests that the G1 and G2 variants may cause kidney injury by increased transport of monovalent cations—similar to the mechanism by which G1 and G2 provide resistance to T brucei.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3–mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147.”
> “Together, these results establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.”

Source: [Datta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/)

<a id="topic-2.2.1.4-3"></a>

### Human genetic evidence: the p.N264K variant blocks pore function

> “A different APOL1 variant, p.N264K, reduced the risk of CKD and ESKD among carriers of APOL1 HR variants to levels comparable with individuals with APOL1 low-risk variants in an analysis of 121,492 participants of African ancestry from the Million Veteran Program (MVP). Functional genetic studies in cell models showed that APOL1 p.N264K blocked APOL1 pore-forming function and ion channel conduction and reduced toxicity of APOL1 HR mutations.”

Source: [Hung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10631602/)

<a id="topic-2.2.1.4-4"></a>

### Podocyte injury, proteinuria, and glomerulosclerosis

> “Risk genotypes overexpressed in podocytes play a crucial role in podocyte injury and correlate with disease severity.3,25 Although podocyte expression of G1/G2 APOL1 and engagement of downstream signaling mechanisms is necessary for glomerulosclerosis, there is a growing body of data for extra-podocyte roles of APOL1 risk variants.”
> “Currently, there are no models of the slowly progressive, low proteinuria, chronic disease that accounts for the vast majority of human APOL1 kidney disease.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “In AMKD, the kidney’s filtering units, known as the glomeruli, and within them the cells known as podocytes, are damaged, leading to leakage of protein into the urine, deterioration in kidney function, scarring, and, ultimately, end stage renal disease.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-2.2.1.4-5"></a>

### Interferon-induced APOL1 expression and second hits

> “Expression of APOL1 is regulated by cytokines (mostly by interferon), inflammation, hypoxia/ischemia, viruses, and nucleic acids.”
> “Nongenetic second hits resulting in glomerular disease include high interferon states, viral infections (HIV and COVID-19), exposure to alpha, beta, or gamma interferon, and APOL1 overexpression,3,6,20,22,68 with high interferon states having the strongest evidence.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “The most established systemic factors are viral infections (for example, HIV) and, more generally, systemic elevations in interferon levels. It is now apparent that APOL1 is expressed in an interferon-dependent manner55.”
> “Kidney disease has also been reported in individuals with APOL1 risk variants after receiving therapeutic interferon138.”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

> “Our results reveal that IFN-γ signaling simultaneously induces endothelial injury and primes renal cells for pyroptosis, suggesting a combinatorial mechanism for APOL1-mediated collapsing glomerulopathy, which can be targeted therapeutically.”

Source: [Juliar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11216883/)

<a id="topic-2.2.1.4-6"></a>

### Downstream cellular injury pathways in experimental models

> “Functions associated with G1 or G2 APOL1 overexpression in cells or mice include ion channel,26 actin cytoskeleton,51,60,61 or mitochondrial dysfunction62; endoplasmic reticulum stress3; reduction of global protein synthesis63,64; suPAR (soluble urokinase plasminogen activator receptor)-dependent activation of integrin65; activation of nucleotide sensors; and inflammation.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Cell and mouse models implicate endolysosomal and mitochondrial dysfunction, altered ion channel activity, altered autophagy, and activation of protein kinase R in the pathogenesis of APOL1-associated kidney disease; however, the relevance of these injury pathways to human disease has not been resolved.”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
